NEW
Cresemba

Cresemba Drug Interactions

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Full Prescribing Info
Drug Interactions
Potential of medicinal products to affect the pharmacokinetics of isavuconazole: Isavuconazole is a substrate of CYP3A4 and CYP3A5 (see Pharmacology: Pharmacokinetics under Actions). Co-administration of medicinal products which are inhibitors of CYP3A4 and/or CYP3A5 may increase the plasma concentrations of isavuconazole. Co-administration of medicinal products which are inducers of CYP3A4 and/or CYP3A5 may decrease the plasma concentrations of isavuconazole.
Medicinal products that inhibit CYP3A4/5: Co-administration of CRESEMBA with the strong CYP3A4/5 inhibitor ketoconazole is contraindicated, since this medicinal product can significantly increase plasma concentrations of isavuconazole (see Contraindications and the following text).
For the strong CYP3A4 inhibitor lopinavir/ritonavir, a two-fold increase in isavuconazole exposure was observed. For other strong CYP3A4 inhibitors, such as clarithromycin, indinavir and saquinavir, a less pronounced effect can be expected, based on their relative potency. No dose adjustment of CRESEMBA is necessary when co-administered with strong CYP3A4/5 inhibitors, however caution is advised as adverse drug reactions may increase (see Precautions).
No dose adjustment is warranted for moderate to mild CYP3A4/5 inhibitors.
Medicinal products that induce CYP3A4/5: Co-administration of CRESEMBA with potent CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long-acting barbiturates (e.g., phenobarbital), phenytoin and St. John's wort, or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine, is contraindicated, since these medicinal products can significantly decrease plasma concentrations of isavuconazole (see Contraindications).
Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone and pioglitazone, may result in mild to moderate decreases of isavuconazole plasma levels; co-administration with mild CYP3A4/5 inducers should be avoided unless the potential benefits is considered to outweigh the risk (see Precautions).
Co-administration with high-dose ritonavir (>200 mg twice daily) is contraindicated, as at high doses ritonavir may induce CYP3A4/5 and decrease isavuconazole plasma concentrations (see Contraindications).
Potential for CRESEMBA to affect exposures of other medicines: Medicinal products metabolized by CYP3A4/5: Isavuconazole is a moderate inhibitor of CYP3A4/5; co-administration of CRESEMBA with medicinal products which are substrates of CYP3A4/5 may result in increased plasma concentrations of these medicinal products.
Medicinal products metabolized by CYP2B6: Isavuconazole is a mild CYP2B6 inducer; co-administration of CRESEMBA may result in decreased plasma concentrations of CYP2B6 substrates.
Medicinal products transported by P-gp in the intestine: Isavuconazole is a mild inhibitor of P-glycoprotein (P-gp); co-administration with CRESEMBA may result in increased plasma concentrations of P-gp substrates.
Medicinal products transported by BCRP: Isavuconazole is an inhibitor in vitro of BCRP, and plasma concentrations of substrates of BCRP may therefore be increased. Caution is advised when CRESEMBA is given concomitantly with substrates of BCRP.
Medicinal products renally excreted via transport proteins: Isavuconazole is a mild inhibitor of the organic cation transporter 2 (OCT2). Co-administration of CRESEMBA with medicinal products which are substrates of OCT2 may result in increased plasma concentrations of these medicinal products.
Uridine diphosphate-glucuronosyltransferases (UGT) substrates: Isavuconazole is a mild inhibitor of UGT. Co-administration of CRESEMBA with medicinal products which are substrates of UGT may result in mildly increase plasma concentrations of these medicinal products.
Interaction table: Interactions between isavuconazole and co-administered medicinal products are listed in Table 4 (increase is indicates as "↑", decrease as "↓"), ordered by therapeutic class. Unless otherwise stated, studies detailed in Table 4 have been performed with the recommended dose of CRESEMBA. (See Table 4.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image


Click on icon to see table/diagram/image
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in